Key Drivers
- Strong cash
- High margins
- Quarterly volatility
AIAI Summary
Harmony's transition from a binary clinical‑stage biotech to a cash‑generating specialty pharma materially lowers solvency risk and recasts the investment thesis around commercial execution and measured M&A optionality, but the key actionable pivot is to watch whether WAKIX sustains >20% y/y growth and GR/HD bioequivalence/readouts occur on schedule—if so, upside is de‑risked; if not, revenue concentration and late‑stage trial risk can compress multiples.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash
- •High margins
- •Quarterly volatility
HRMY demonstrates strong annual liquidity, high margins and substantial free cash flow with low leverage and attractive valuation, but faces quarterly margin volatility and elevated operating spend.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Near support cluster
- •Downward momentum
HRMY is in a mild short-term downtrend—trading below last month's 21-day SMA (~$28.27), near the low of that range and biased toward support at $27.60–$27.90, with immediate resistance $29.00–$29.20 and limited near-term downside unless the support cluster breaks.
Trading near the low of last month with a steady decline from late‑February highs
Sentiment & News
Key News Insights:
- •Revenue ramp
- •EPS miss
- •>$1B guidance
Harmony Biosciences posted strong 2025 revenue growth driven by WAKIX and reiterated >$1B 2026 guidance, but missed Q4 EPS ($0.38 vs $0.84 est.).
Expect mixed market reaction—top-line momentum and bullish guidance support the stock, while the EPS shortfall could pressure near-term performance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings